- Home
- OXSQ vs IPHA Comparison
OXSQ vs IPHA Comparison
Compare OXSQ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- IPHA
- Stock Information
- Founded
- OXSQ 2003
- IPHA 1999
- Country
- OXSQ United States
- IPHA France
- Employees
- OXSQ N/A
- IPHA N/A
- Industry
- OXSQ Blank Checks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- OXSQ Finance
- IPHA Health Care
- Exchange
- OXSQ Nasdaq
- IPHA Nasdaq
- Market Cap
- OXSQ 190.1M
- IPHA 160.1M
- IPO Year
- OXSQ N/A
- IPHA 2019
- Fundamental
- Price
- OXSQ $2.47
- IPHA $2.43
- Analyst Decision
- OXSQ
- IPHA Strong Buy
- Analyst Count
- OXSQ 0
- IPHA 1
- Target Price
- OXSQ N/A
- IPHA $11.00
- AVG Volume (30 Days)
- OXSQ 440.9K
- IPHA 31.8K
- Earning Date
- OXSQ 04-25-2025
- IPHA 03-27-2025
- Dividend Yield
- OXSQ 17.07%
- IPHA N/A
- EPS Growth
- OXSQ N/A
- IPHA N/A
- EPS
- OXSQ N/A
- IPHA N/A
- Revenue
- OXSQ $42,166,831.00
- IPHA $20,831,349.00
- Revenue This Year
- OXSQ $8.73
- IPHA $209.83
- Revenue Next Year
- OXSQ N/A
- IPHA $83.96
- P/E Ratio
- OXSQ N/A
- IPHA N/A
- Revenue Growth
- OXSQ N/A
- IPHA N/A
- 52 Week Low
- OXSQ $2.28
- IPHA $1.29
- 52 Week High
- OXSQ $3.28
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- OXSQ 43.43
- IPHA 67.63
- Support Level
- OXSQ $2.44
- IPHA $2.22
- Resistance Level
- OXSQ $2.48
- IPHA $2.45
- Average True Range (ATR)
- OXSQ 0.05
- IPHA 0.14
- MACD
- OXSQ 0.00
- IPHA 0.03
- Stochastic Oscillator
- OXSQ 21.87
- IPHA 82.52
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing, and Diversified Insurance.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.